MedWatch

Demant's divestment of implant business drags out

Cochlear will have to wait longer to get its hands on the Danish hearing aid manufacturer’s implants division, as the planned acquisition now won’t be completed before 2023.

Photo: Demant / PR

In April, Demant announced it was selling its Hearing Implants division, which the Danish hearing aid manufacturer had had for 15 years, to Cochlear for DKK 850m (USD 112m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs